Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$509.00K$509.00Kderived−1.2% vs Q4 2017 Net Income-$1.38M-$1.38MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,376,000N/M Operating Cash Flowderived-$664,000N/M Free Cash Flowderived-$664,000N/M Margins · derivedOperating margin-270.3%+4.2 pt vs Q4 2017
Net margin-271.9%+86.5 pt vs Q4 2017
ended Jul 31, 2018 · filed Oct 25, 2018 · 86 d after period end